Harnessing molecular vulnerabilities to promote an antitumor immune microenvironment (C02+)

利用分子脆弱性促进抗肿瘤免疫微环境（C02）

• 批准号: 426797451
• 金额: --
• 依托单位: Klinik für Hämatologie und Stammzelltransplantation
• 依托单位国家: 德国
• 项目类别: Collaborative Research Centres
• 财政年份: 2019
• 资助国家: 德国
• 起止时间: 2018-12-31 至 2022-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/426797451?language=en
• 关键词: Harnessing; molecular; vulnerabilities; promote; antitumor

In the project G. Herter-Sprie and C. Reinhardt will employ a next generation genetically engineered mouse model to analyze the role of genomic instability on SCLC immunogenicity and thereby immune surveillance, identify whether radiation and chemotherapy influence the sensitivity towards immunological modulation, and characterize the anti-tumor efficacy of PD-1:PD-L1-blocking antibodies, upon prior regulatory T cells (TReg) repression. Ultimately, the findings from this project will help clinicians to design informed patient-tailored clinical studies.

In the project G. Herter-Sprie and C. Reinhardt will employ a next generation genetically engineered mouse model to analyze the role of genomic instability on SCLC immunogenicity and thereby immune surveillance, identify whether radiation and chemotherapy influence the sensitivity towards immunological modulation, and characterize the anti-tumor efficacy of PD-1:PD-L1-blocking antibodies, upon prior regulatory T cells (TReg)镇压。最终，该项目的发现将有助于临床医生设计知情的患者调整临床研究。